[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Demaod Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100624876","lacrima-vr-for-dry-eye-disease-and-meibomian-gland-dysfunction-100624876",false,"NCT07415330","Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction","A Randomized, Masked (Evaluator), Sham-Controlled, Prospective Study to Evaluate the Safety and Effectiveness of the Lacrima VR System in Subjects With Dry Eye Disease and Meibomian Gland Dysfunction","CLN-0154","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Ability to provide written informed consent\n* Willingness and ability to comply with study procedures and visits\n* Self-reported dry eye symptoms for at least 3 months\n* OSDI score ≥ 23 at baseline\n* Tear Break-Up Time (TBUT) \\\u003C 10 seconds in both eyes\n\nExclusion Criteria:\n\n* Ocular surgery within 1 year prior to screening\n* Active ocular infection or inflammation\n* History of ocular herpes infection within the past 3 months\n* Use of contact lenses within 3 months prior to screening or during the study\n* Use of prohibited dry eye or MGD treatments within protocol-defined washout periods\n* Diagnosis of epilepsy\n* Intraocular pressure \\> 20 mmHg\n* Pregnancy or breastfeeding","ALL","18 Years","120 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.",[28,29],"Dry Eye","Dry Eye Syndromes","NOT_YET_RECRUITING","2026-05-11",{"date":33,"type":34},"2026-05-12","ACTUAL",{"date":36,"type":22},"2026-07-20",{"date":38,"type":22},"2026-09-01",{"name":40,"class":41},"Demaod Ltd","INDUSTRY",""]